Anixa Biosciences is a biotechnology company developing therapies and vaccines that are focused on unmet needs in oncology and infectious disease. Co.'s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a form of chimeric antigen receptor T-cell technology, initially focused on treating ovarian cancer, and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Co.'s vaccine programs include the development of a vaccine against triple negative breast cancer and a vaccine against ovarian cancer. The ANIX stock yearly return is shown above.
The yearly return on the ANIX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANIX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|